Where the stock stands
Alembic Pharmaceuticals Limited (APLLTD) trades at a price-to-earnings ratio of 24.55 and a price-to-book ratio of 2.92, with earnings per share of ₹34.32. The company reports a return on equity of 12.4% and carries a market capitalisation of ₹16,563 crore. The dividend yield stands at 1.42%. The data does not specify which sector classification applies, though the company's name and regulatory filings indicate pharmaceutical operations. Against the broader market, the Nifty declined 0.39% as of the latest data date of 20 July 2026.
What the smart-money flow shows
The evidence pack contains no data on futures and options positioning, open interest changes, or long/short buildup patterns. No bulk deals or block deals are recorded. There are no named institutional investor transactions, no streaks of foreign or domestic institutional buying or selling, and no promoter or insider trading filings disclosed. The data shows no recent insider filings. Without this information, the directional commitment of sophisticated market participants cannot be characterised.
The technical picture
No technical indicators, price levels, moving averages, volume trends, or chart patterns are provided in the evidence pack. Support and resistance zones, relative strength readings, and momentum signals are absent. The data does not establish any technical positioning for the stock.
Catalysts and what to watch
The company has reported multiple USFDA regulatory approvals in recent weeks. According to exchange filings dated 18 July 2026, Alembic Pharmaceuticals' partner NATCO Pharma received tentative USFDA approval for Olaparib Tablets in 100 mg and 150 mg strengths. Earlier, on 26 June 2026, the company announced final USFDA approval for Dapsone Gel, 5%. News headlines from Sahi report that Alembic Pharma won final USFDA approval for Levothyroxine targeting a $1.87 billion US market, according to a headline from 59 days ago. A Reuters headline from 66 days ago noted that quarterly profit rose on strong US generics demand, while a TradingView headline from the same period reported revenue, profit and margin improvement year-over-year with dividend increased to ₹12 per share. What the data does not establish is whether these approvals are already priced in, the revenue contribution timelines for these products, or any pending regulatory pipeline. Investors would need to track further ANDA approvals, partnership milestones with NATCO, and quarterly earnings progression to assess operational impact.